Mesna

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Mucolytic, mucosal protector.

Half-lifeThis section has been translated automatically.

1,5 h

IndicationThis section has been translated automatically.

Prophylaxis of the urotoxicity of oxazaphosphorins (e.g. cyclophosphamide).

Limited indicationThis section has been translated automatically.

patients with autoimmune diseases (increased risk of allergic reactions).

Dosage and method of useThis section has been translated automatically.

Inject 20% of the oxazaphosphorin dose at time 0 (= injection of the cytostatic drug), 4 and 8 hours i.v.

Undesirable effectsThis section has been translated automatically.

Allergic reactions, temporary increases in transaminases, vein irritation at the injection site, gastrointestinal disturbances, drop in blood pressure, tachycardia.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, hypersensitivity to thiol compounds.

PreparationsThis section has been translated automatically.

Uromitexane

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer